Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Recruiting

• Conditions: Hospitalized Patients
• Interventions: Drug: Nirmatrelvir-Ritonavir

• Registration Number: NCT05749445
• Lead Sponsor: First People's Hospital of Hangzhou

Brief Summary

The primary objective of the study was to assess the appropriateness of antiviral therapy with nirmatrelvir-ritonavir in hospitalized patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-15
• Status Verified: 2023-02
• Study First Submitted: 2023-02-16
• Study First Submitted QC: 2023-02-26
• Last Update Submitted: 2023-02-26
• Study First Posted: 2023-03-01
• Last Update Posted: 2023-03-01
• Primary Completion: 2023-04
• Study Completion: 2023-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• hospitalized patients receiving at least one dose nirmatrelvir-ritonavir

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Nirmatrelvir-Ritonavir	Nirmatrelvir-Ritonavir	Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir

Primary Outcome Measures

Name	Time	Method
The prevalence of inappropriate use of nirmatrelvir-ritonavir	baseline	Four aspects were evaluated to identify the rationality of prescribing NMVr, including indication, administration (dose, timing, and duration), contraindications, and drug-drug interactions.

Trial Locations

Locations (1)

Changcheng Shi; 🇨🇳 Hangzhou, Zhejiang, China